Markets closed

Amgen Inc.

AMGN · Nasdaq

Analyst Consensus

Hold

24 analysts

$417

Current

—

Low

$390

Average

—

High

Average target implies -6.52% versus the current price.

Analyst Ratings Synthesis

Consensus is Hold, supported by 24 analysts. The available target data show a mean of $370, while the low and high targets are not reported, so the target distribution and its spread cannot be quantified. The evidence does not identify the most bullish or least bullish analyst, nor does it document any rating or target revisions during the week. The substantive published debate is therefore only partly visible: Amgen's second-quarter earnings and revenue beats, 37% Repatha sales growth, and higher 2026 earnings guidance contrast with a Hold consensus and a mean target below the latest $390.02 close.

Rating Actions

No individual rating actions have been captured for AMGNyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

BARCLAYS CAPITA

BMO CAPITAL MKT

CO FORECST

DAIWA AMERICA

DEUTSCHE BK SEC

EDWARD JONES

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MIZUHO SECURITI

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RBC CAPITAL

ROTHSCHILD REDB

TD COWEN

TRUIST SECURITI

UBS

WELLS FARGO SEC

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: AMGN
Type: Stock
Sector: Health Care
Industry: Biological Products, (No Diagnostic Substances)
Exchange: Nasdaq

Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions. Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes.

Key Issues

Bullish view

Amgen exceeded second-quarter earnings and revenue expectations by 12.32% and 6.52%, respectively, and raised 2026 earnings guidance. Those results support the view that operating momentum is improving.

Bearish view

The evidence confirms a single-quarter beat and higher guidance but does not establish how durable the improvement will be. Without the size or details of the guidance increase, the earnings outlook remains difficult to assess.

Analyst Consensus

See all

Hold

24 analysts

$417

Current

—

Low

$390

Average

—

High

Average target implies -6.52% versus the current price.

Earnings History

BeatMissNo estimate

Amgen Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers